Verona Pharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · United Kingdom · 201-500 Employees
View Company Info for Free
Overview
Headquarters
3 More London Riverside, London, Greater...Phone Number
(844) 341-9901Website
www.veronapharma.comRevenue
$221.7 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Verona Pharma
Verona Pharma is a biopharmaceutical company dedicated to developing innovative treatments for chronic respiratory diseases, including COPD, asthma, and cystic fibrosis. Their lead product, ensifentrine, is focused on enhancing the quality of life for patients suffering from these conditions. The company places an emphasis on patient insights and educational resources to improve respiratory care. Verona Pharma aims to bring novel therapeutics to the market to address the unmet needs of individuals affected by chronic lung diseases.Explore more
Verona Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Verona Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Verona Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Verona Pharma is spiking on competitors!
Check if Verona Pharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Verona Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Verona Pharma
Earning: See what the market has to say on Verona Pharma recently announced quarterly report
Click to see if Verona Pharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Verona Pharma has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Verona Pharma
Compare insights from companies similar to Verona Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$216.8M
51-200
Public
$1.1B
1991
SK
Stephen KetchumExecutive VP & President, Research & Development & Chief Scientific Officer
Company Profile Activity
Activity Insights
Verona Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Verona Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Verona Pharma.
Verona Pharma financials insights
Gather financial insights about Verona Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$200M
Debt
$30M
2022
Debt
$150M
2025
Debt
$100M
Verona Pharma Tech Stack
A closer look at the technologies used by Verona Pharma
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves, Board of Directors
Verona Pharma News & Media
Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend
Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest. The $10 billion acquisition of Verona Pharma plc (NASDAQ:VRNA) by Merck & Co. (NYSE:MRK), which offered $107 per American Depositary Share, was authorized by the company’s shareholders on October 1. After a planned […]Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), known as Merck in the U.S. and Canada, through a wholly owned subsidiary or a nominee, today announced that the High Court of Justice ofVerona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio
We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Verona Pharma plc is one of them. Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company developing therapies for respiratory diseases. Its lead product, Ohtuvayre (ensifentrine), is a first-in-class inhaled dual inhibitor of PDE3 and PDE4 for maintenance treatment of […]
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Verona Pharma
Sign Up For FreeTo access detailed company insights
Verona Pharma is a biopharmaceutical company dedicated to developing innovative treatments for chronic respiratory diseases, including COPD, asthma, and cystic fibrosis. Their lead product, ensifentrine, is focused on enhancing the quality of life for patients suffering from these conditions. The company places an emphasis on patient insights and e... Read More
